Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
In development [GID-TA10672] Expected publication date: TBC
In development [GID-TA10672] Expected publication date: TBC
In development [GID-TA10072] Expected publication date: 19 May 2021
In development [GID-TAG430] Expected publication date: 24 February 2021
In development [GID-TA10613] Expected publication date: 13 October 2021
In development [GID-TA10520] Expected publication date: 15 September 2021
In development [GID-TA10671] Expected publication date: TBC
In development [GID-TA10302] Expected publication date: 27 January 2021
In development [GID-TA10743] Expected publication date: 17 November 2021
In development [GID-TA10456] Expected publication date: 27 January 2021
In development [GID-TA10622] Expected publication date: 03 February 2021
In development [GID-TA10451] Expected publication date: TBC
In development [GID-TA10478] Expected publication date: 22 September 2021
In development [GID-TA10276] Expected publication date: TBC
In development [GID-TA10532] Expected publication date: TBC
In development [GID-TA10534] Expected publication date: TBC
In development [GID-TA10610] Expected publication date: 02 March 2022
In development [GID-TA10645] Expected publication date: 10 August 2022
In development [GID-TA10663] Expected publication date: 01 June 2022
In development [GID-TA10510] Expected publication date: 24 March 2021
In development [GID-TA10556] Expected publication date: 17 November 2021
In development [GID-TA10560] Expected publication date: 03 February 2021
In development [GID-TA10412] Expected publication date: 13 January 2021
In development [GID-TA10334] Expected publication date: 24 March 2021
In development [GID-TA10305] Expected publication date: 31 March 2021
In development [GID-TA10371] Expected publication date: TBC
In development [GID-TA10455] Expected publication date: 03 February 2021
In development [GID-TA10586] Expected publication date: TBC
In development [GID-TA10485] Expected publication date: 23 June 2021
In development [GID-TA10670] Expected publication date: TBC
In development [GID-TA10713] Expected publication date: TBC
In development [GID-TA10551] Expected publication date: 10 February 2021
In development [GID-TA10651] Expected publication date: 02 February 2022
In development [GID-TA10529] Expected publication date: 10 March 2021
In development [GID-TA10710] Expected publication date: TBC
In development [GID-TA10312] Expected publication date: 24 February 2021
In development [GID-TA10734] Expected publication date: TBC
In development [GID-TA10481] Expected publication date: 18 August 2021
In development [GID-TA10541] Expected publication date: 24 February 2021
In development [GID-TA10373] Expected publication date: 21 April 2021
In development [GID-TA10498] Expected publication date: 13 October 2021
In development [GID-DT28] Expected publication date: TBC
In development [GID-DT9] Expected publication date: TBC
In development [GID-DT14] Expected publication date: TBC
Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)
Evidence-based recommendations on structural neuroimaging for treating first-episode psychosis
Evidence-based recommendations on rituximab for treating relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma in adults
Evidence-based recommendations on onhaled corticosteroids for treating chronic asthma in adults and children aged 12 years and over
Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome
Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)